WealthBridge Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

WealthBridge Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-400	Closed	-$34K	–	891
2019 Q1	$34K	Hold	400	–	–	0.02%	353
2018 Q4	$29K	Buy	+400	New	+$32.2K	0.02%	339

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

WealthBridge Capital Management's XBI Position: Q2 2019 in Review

WealthBridge Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2019, closing a stake of 400 shares — an estimated $34K sold.

WealthBridge Capital Management first reported a position in XBI in Q4 2018 and held it in 2 quarters. The position peaked at $34K in Q1 2019. 424 funds tracked by Wall St. Rank hold XBI as of Q2 2019.

WealthBridge Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2019 after selling out during the quarter.
WealthBridge Capital Management sold 400 State Street SPDR S&P Biotech ETF shares in Q2 2019, an estimated $34K.
WealthBridge Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and held it in 2 quarters.
WealthBridge Capital Management's State Street SPDR S&P Biotech ETF position peaked at $34K in Q1 2019.
424 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2019.

Based on WealthBridge Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.